|
Index | - | P/E | - | EPS (ttm) | -2.35 | Insider Own | 7.08% | Shs Outstand | 14.42M | Perf Week | -3.00% |
Market Cap | 243.45M | Forward P/E | - | EPS next Y | -1.77 | Insider Trans | 4.75% | Shs Float | 12.80M | Perf Month | 10.14% |
Income | -28.50M | PEG | - | EPS next Q | -0.49 | Inst Own | 83.70% | Short Float | 1.02% | Perf Quarter | 2.06% |
Sales | 17.40M | P/S | 13.99 | EPS this Y | 2.60% | Inst Trans | -0.46% | Short Ratio | 5.62 | Perf Half Y | 10.91% |
Book/sh | 3.91 | P/B | 4.06 | EPS next Y | 18.40% | ROA | -36.00% | Target Price | 20.00 | Perf Year | 9.00% |
Cash/sh | 5.31 | P/C | 2.99 | EPS next 5Y | - | ROE | -65.10% | 52W Range | 5.25 - 23.55 | Perf YTD | 5.45% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | -31.30% | 52W High | -32.26% | Beta | - |
Dividend % | - | Quick Ratio | 15.90 | Sales past 5Y | - | Gross Margin | 60.50% | 52W Low | 203.81% | ATR | 0.96 |
Employees | 89 | Current Ratio | 16.70 | Sales Q/Q | 32.50% | Oper. Margin | - | RSI (14) | 54.01 | Volatility | 7.38% 5.63% |
Optionable | No | Debt/Eq | 0.55 | EPS Q/Q | 9.40% | Profit Margin | - | Rel Volume | 0.41 | Prev Close | 15.86 |
Shortable | Yes | LT Debt/Eq | 0.55 | Earnings | - | Payout | - | Avg Volume | 23.32K | Price | 15.95 |
Recom | 1.50 | SMA20 | 3.73% | SMA50 | 5.84% | SMA200 | 4.14% | Volume | 6,000 | Change | 0.57% |
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite